Brink Therapeutics is a technology company.
Brink Therapeutics has raised $4.0M across 1 funding round.
Brink Therapeutics has raised $4.0M in total across 1 funding round.
Brink Therapeutics has raised $4.0M in total across 1 funding round.
Brink Therapeutics's investors include Breega, Kima Ventures, Kurma Partners, Jonathan Widawski, Rand Hindi.
Brink Therapeutics is a Paris-based biotech startup founded in 2024 that develops next-generation gene editing enzymes called recombinases to enable advanced cell and gene therapies, particularly for CAR-T treatments targeting hematological cancers, solid tumors, and rare genetic diseases.[1][2] The company addresses limitations of traditional gene-editing tools like programmable nucleases by using recombinases—precise enzymes that modify DNA without double-strand breaks—enhanced through directed evolution, metagenomic discovery, and AI-driven design for programmable, scalable genetic modifications.[1][2] Initially focusing on CAR-T cell therapies, Brink serves patients with hard-to-treat cancers and genetic disorders by enabling safer in vivo genome editing, with early momentum from a €3.5 million seed round in 2025 led by Kurma Partners to expand its team to 15 specialists and validate five novel recombinases by end-2026.[1][2]
Brink Therapeutics was founded in September 2024 by Dr. Jonathan Naccache (ESPCI) and Dr. Harry Kemble (INSERM/ESPCI), two accomplished scientists whose prior work contributed to the success of the diagnostic startup Detect.[1] The idea emerged from their expertise in molecular and cellular biology, aiming to pioneer recombinase-based gene editing as a safer alternative to existing "genetic scissors" that risk off-target effects and genomic instability.[1][2] Early traction came swiftly with the €3.5 million seed funding in 2025, backed by Kurma Partners, Kima Ventures, BREEGA, Plug and Play Tech Center, and business angels, providing capital to build a data library for AI-driven enzyme design and kickstart R&D.[2]
Brink Therapeutics rides the wave of next-generation gene editing, where recombinases address CRISPR's limitations like off-target cuts and delivery challenges, aligning with the booming CAR-T market projected to expand amid demands for in vivo therapies that treat patients without ex vivo cell extraction.[1][2][3] Timing is ideal post-2024 funding surge in European biotech, fueled by AI integration in drug discovery and investor focus on precision medicine from firms like Kurma Partners, which targets innovative therapeutics.[2] Market forces favoring Brink include rising solid tumor therapy needs and rare disease investments, positioning the company to influence the ecosystem by open-sourcing data insights or partnering for scalable production, much like prior gene-editing pioneers.[1][2]
Brink's near-term path centers on hitting 2026 recombinase milestones, team scaling, and AI data library expansion to prototype CAR-T candidates, potentially attracting Series A funding amid Europe's biotech momentum.[1][2] Trends like AI-optimized enzymes and in vivo cell therapies will propel growth, evolving Brink from a seed-stage innovator to a platform leader partnering with big pharma for global trials. As a fresh entrant solving gene editing's precision bottleneck, Brink exemplifies how founder-driven science can redefine accessible therapies, echoing its Detect roots in transformative biotech.
Brink Therapeutics has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2025 | $4.0M Seed | Breega, Kima Ventures, Kurma Partners, Jonathan Widawski, Rand Hindi |